Learner Annual Lear																	CIC)MS	S F	OR	₹M
L. REACTION INFORMATION L. PARICH PRIVACY COSTA RICA Day																					
L. REACTION INFORMATION L. PARICH PRIVACY COSTA RICA Day RAVING Day RAVING RAVING RAVING Day Day RAVING Day Day RAVING Day RAVING Day RAVING Day RAVING Day Day RAVING Day Day RAVING Day RA	SUSPECT ADVERSE REACTION REPORT																				\dashv
1. SUBSECT DRUGS (entire speech rate)	SUSFECT ADVERSE REACTION REPORT								_		_			_	_		_			_	
1. SUBSECT DRUGS (entire species reset) 1. SUBSECT DRUGS (include variation of the state																					
1. SUBSECT DRUGS (entire specific result) Study (1. 199-NovoDia S					DEA	CTION	LINEOD	NANTION	. I	'		-			-					•	_
PRIVACY COSTA RICA Use PRIVACY WE 46 Female 81,00 199 APR 2025 7.13 (PRIVACY COSTA RICA WAS ASSESSED ASSESSE	1. PATIENT INITIALS	1a. COUNTRY	2.			1	1	1		1-6 RE	EACTION	N ON	ISET	8-12	2	CHEC	CK ALL				
T. ISOSECRIBS REACTIONING precises from the least of product use in unapproved indication		COSTA RICA					Eomolo	81.00	Da	ıy						APPR	ROPRIA				
Diarrhee [Diarrhoea] Headaches [Headaches] Ozempic use for Overweight and insulin resistance [Product use in unapproved indication] Case Description: ""This is an auto generated narrative"" Study ID: 199-NovoDia Study Gentinued on Additional Information Page) II. SUSPECT DRUG(S) INFORMATION II. SUSPECT DRUG(S) INFORMATION II. SUSPECT DRUG(S) INFORMATION III. SUSPECT DRUG	PATIENT DIED																				
Headaches [Headaches] Case plescription: ""This is an auto generated narrative"" Case Description: ""This is an auto generated narrative"" Study ID: 199-NovoDia Study description: Trial Title: Patient support programme to support (Continued on Additional Information Page) II. SUSPECT DRUG(S) INFORMATION 14. SUSPECT DRUG(S) INFORMATION 15. Semaglutide B 1.34 mg/ml PDS290 0.25/0.5 mg (SEMAGLUTIDE 1.34 mg/ml.) Solution for injection (Continued on Additional Information Page) 16. DAILY DOSE(S) 17. NORCHTONING FOR USE 47.1 OVErweight (Overweight) 18. TRICKAPY DUSTEDIENTED 19. TRICKAPY CURSTION 19. TRICKA															_						
Ozempic use for Overweight and insulin resistance (Product use in unapproved indication) Case Description: ""This is an auto generated narrative"" Insurance	, · · · ·								ָן	HOSPITALISATION											
Case Description: "*This is an auto generated narrative"** Study ID: 199-NovoDia Study description: Trial Title: Patient support programme to support (Continued on Additional Information Page) II. SUSPECT DRUG(S) INFORMATION 15. SUSPECT DRUG(S) (include genetic same) #1) Semaglutide B 1.34 mg/ml PDS280 0.25/0.5 mg (SEMAGLUTIDE 1.34 mg/ml). Solution for injection (Continued on Additional Information Page) 15. DARY DOSE(S) 17. INDICATIONIS FOR USE 18. INDICATIONIS FOR USE 19. INDICATIONIS FOR USE 19. INDICATIONIS FOR USE 19. INDICATIONIS FOR USE 19. INDICATIONIS FOR USE	1 · · · · · · · · · · · · · · · · · · ·								OR SIGNIFICANT DISABILITY OR												
Study description: Trial Title: Patient support programme to support Continued on Additional Information Page	Case Description	: ***This is an auto	genera	ated narr	ative***										LIFE LIFE						
Continued on Additional Information Page OTHER	Study ID: 199-No	voDia												16							
II. SUSPECT DRUG(S) INFORMATION 14. SUSPECT DRUG(S) INFORMATION 15. DRUGGE penetric name	Study description	: Trial Title: Patient	suppo	rt progra	mme to	support								-							
14. SUBSECT DRUGS) (include generic name) #1 Semagliutide B 1.34 mg/ml PDS290 0.25/0.5 mg (SEMAGLUTIDE 1.34 mg/ml Solution for injection (Continued on Additional Information Page) 15. DAILY DOSE(S) 16. ROUTE(S) OF ADMINISTRATION 17. INDICATIONS) FOR USE 17. INDICATIONS) FOR USE 17. INDICATIONS) FOR USE 18. THERAPY DATES (promise) 18. THERAPY DATES (promise) 18. THERAPY DATES (promise) 19. THERAP							(Cont	inued on Ad	dditio	nal Ir	format	tion	Pag	e) L	_						
## 1) Semaglutide B 1.34 mg/ml PDS290 0.25/0.5 mg (SEMAGLUTIDE 1.34 mg/ml.) Solution for injection (Continued on Additional Information Page) 15. DAILY DOSE(S) 17. INDICATION(S) FOR USE 17. INDICATION(S) FOR USE 17. Overweight (Overweight) 18. THERAPY DURATION 19. THERAPY DURATION 22. CONCONITANT DRUG(S) AND HISTORY 22. CONCONITANT DRUG(S) AND HISTORY 23. OTHER RELEVANT HISTORY, (e.g. diagnostics, slergies, pregnancy with last month of period, dic.) 24. THERAPY DURATION 25. THERAPY DURATION 26. THERAPY DURATION 27. THERAPY DURATION 28. REMARKS 28. REMARKS 28. MANUFACTURER INFORMATION 28. REMARKS 28. REMARKS 29. MANUFACTURER 240. MFR CONTROL NO. 250. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD. 261. NAME AND ADDRESS WITHHELD. 262. NAME AND ADDRESS WITHHELD. 263. NAME AND ADDRESS WITHHELD.				II. SU	SPEC	T DRU	JG(S) IN	FORM <i>A</i>	ATIO	N											
15. DAILY DOSE(S)			0 0.25	/0.5 ma (§	SEMAGI	LUTIDE	1.34 ma/ml	_) Solution	for in	iecti	on			- 1	ABA	TE AF		TOPF	PING		
## 1) UNIK #1) Subcutaneous							•	• ,							DKU	JG?					
#1) Overweight (Overweight) (Continued on Additional Information Page) 18. THERAPY DURATION #1) JAPR-2025 / Unknown 19. THERAPY DURATION #1) Unknown 19. THERAPY DURATION 19. THERAPY D															YES	NO	> D	NA			
##) Overweight (Overweight) (Continued on Additional Information Page) 18. THERAPY DURATION #1) Unknown 19. THERAPY DURATION																		FR			_
#1) APR-2025 / Unknown	#1) Overweight (C	Overweight)					(Cont	inued on Ad	dditio	nal Ir	ıformat	tion	Pag								
III. CONCOMITANT DRUG(S) AND HISTORY 22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) #1) VITAMIN D3 (VITAMIN D3) ; Ongoing 23. OTHER RELEVANT HISTORY, (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) From/To Dates Type of History / Notes Description Unknown to Ongoing Current Condition Overweight (Overweight) Unknown to Ongoing IV. MANUFACTURER INFORMATION 24a. NAME AND ADDRESS OF MANUFACTURER NOVO Nordisk A/S Lise Grimmeshave Vandtaarnsveig 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888 24b. MFR CONTROL NO. 1439736 24c. DATE RECEIVED BY MANUFACTURER STUDY HEALTH PROFESSIONAL OTHER: OTHER: DATE OF THIS REPORT 25a. REPORT TYPE													П	YES	Пм	э Б	7 NA				
22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) #1) VITAMIN D3 (VITAMIN D3); Ongoing 23. CITHER RELEVANT HISTORY, (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) From/To Dates Type of History / Notes Description Overweight (Overweight) Unknown to Ongoing Unknown to Ongoing Unknown to Ongoing Unknown to Ongoing UN. MANUFACTURER INFORMATION 24a. NAME AND ADDRESS OF MANUFACTURER Novo Nordisk A/S Lise Grimmenshave Vandtaarmsvej 114 Soeborg, DAZES60 DENMARK Phone: +45 44448888 24b. MFR CONTROL NO. 1439736 24c. DATE RECEIVED BY MANUFACTURER 24d. REPORT SOURCE STUDY HITERATURE STUDY LITERATURE UTERATURE	#1) AFR-2023 / OHKHOWH #1) UNKNOWH																				
22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) #1) VITAMIN D3 (VITAMIN D3); Ongoing 23. CITHER RELEVANT HISTORY, (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) From/To Dates Unknown to Ongoing UNKNOWN to Ong			III	. CON	COMIT	TANT [DRUG(S) AND H	HIST	OR	Υ										
23. OTHER RELEVANT HISTORY, (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) From/To Dates Unknown to Ongoing Current Condition Overweight (Overweight) Unknown to Ongoing Current Condition Insulin resistance (Insulin resistance) IV. MANUFACTURER INFORMATION			MINISTRA	TION (exclud				<i>)</i>		_	•										
Type of History / Notes Unknown to Ongoing IV. MANUFACTURER INFORMATION 24a. NAME AND ADDRESS OF MANUFACTURER Novo Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888 24b. MFR CONTROL NO. 1439736 24c. DATE RECEIVED BY MANUFACTURER STUDY HEALTH PROFESSIONAL OTHER: DATE OF THIS REPORT 25a. REPORT TYPE	#1) VITAMIN บัง 	(VITAMIN D3) ; C	ngoin	g																	
Type of History / Notes Unknown to Ongoing IVKNOWN																					
Type of History / Notes Unknown to Ongoing IVKNOWN																					
Type of History / Notes Unknown to Ongoing IV. MANUFACTURER INFORMATION 24a. NAME AND ADDRESS OF MANUFACTURER Novo Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888 24b. MFR CONTROL NO. 1439736 24c. DATE RECEIVED BY MANUFACTURER STUDY HEALTH PROFESSIONAL OTHER: DATE OF THIS REPORT 25a. REPORT TYPE																					_
Unknown to Ongoing Current Condition Insulin resistance (Insulin resistance) IV. MANUFACTURER INFORMATION 24a. NAME AND ADDRESS OF MANUFACTURER Novo Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888 24b. MFR CONTROL NO. 1439736 24c. DATE RECEIVED BY MANUFACTURER STUDY LITERATURE PROFESSIONAL OTHER: DATE OF THIS REPORT 25a. REPORT TYPE	From/To Dates		T	ype of History	y / Notes	•	Description	11 (Ours													
24a. NAME AND ADDRESS OF MANUFACTURER Novo Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888 24b. MFR CONTROL NO. 1439736 24c. DATE RECEIVED BY MANUFACTURER 20-MAY-2025 24d. REPORT SOURCE STUDY LITERATURE 20-MAY-2025 25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD. 25b. NAME AND ADDRESS WITHHELD.		- · · · · · · · · · · · · · · · · · ·																			
24a. NAME AND ADDRESS OF MANUFACTURER Novo Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888 24b. MFR CONTROL NO. 1439736 24c. DATE RECEIVED BY MANUFACTURER 20-MAY-2025 24d. REPORT SOURCE STUDY LITERATURE 20-MAY-2025 25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD. 25b. NAME AND ADDRESS WITHHELD.																					
24a. NAME AND ADDRESS OF MANUFACTURER Novo Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888 24b. MFR CONTROL NO. 1439736 24c. DATE RECEIVED BY MANUFACTURER 20-MAY-2025 24d. REPORT SOURCE STUDY LITERATURE OTHER: DATE OF THIS REPORT 25a. REPORT TYPE																					
24a. NAME AND ADDRESS OF MANUFACTURER Novo Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888 24b. MFR CONTROL NO. 1439736 24c. DATE RECEIVED BY MANUFACTURER 20-MAY-2025 24d. REPORT SOURCE STUDY LITERATURE OTHER: DATE OF THIS REPORT 25a. REPORT TYPE																					_
Novo Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888 24b. MFR CONTROL NO. 1439736 24c. DATE RECEIVED BY MANUFACTURER 20-MAY-2025 24d. REPORT SOURCE STUDY LITERATURE OTHER: DATE OF THIS REPORT 25a. REPORT TYPE																					
Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888 24b. MFR CONTROL NO. 1439736 24c. DATE RECEIVED BY MANUFACTURER 20-MAY-2025 24d. REPORT SOURCE STUDY HEALTH PROFESSIONAL OTHER: DATE OF THIS REPORT 25a. REPORT TYPE	Novo Nordisk A/S							med:	No												
Phone: +45 44448888 24b. MFR CONTROL NO. 1439736 24c. DATE RECEIVED BY MANUFACTURER 20-MAY-2025 24d. REPORT SOURCE STUDY LITERATURE OTHER: DATE OF THIS REPORT 25a. REPORT TYPE	Vandtaarnsvej 114																				
1439736 24c. DATE RECEIVED BY MANUFACTURER 20-MAY-2025 ATERIC FIHIS REPORT 25a. REPORT TYPE NAME AND ADDRESS WITHHELD. NAME AND ADDRESS WITHHELD. PROFESSIONAL OTHER:	Debutg, Dr2600 DENMARK Phone: +45 44448888																				
1439736 24c. DATE RECEIVED BY MANUFACTURER 20-MAY-2025 ATERIC FIHIS REPORT 25a. REPORT TYPE NAME AND ADDRESS WITHHELD. NAME AND ADDRESS WITHHELD. PROFESSIONAL OTHER:																					
24c. DATE RECEIVED BY MANUFACTURER 20-MAY-2025 DATE OF THIS REPORT 24d. REPORT SOURCE STUDY LITERATURE OTHER: 25a. REPORT TYPE 25a. REPORT TYPE				۱0.).								
20-MAY-2025 DATE OF THIS REPORT 25a. REPORT TYPE 25a. REPORT TYPE	240 DATE RECEIVED			<u> </u>			_														
DATE OF THIS REPORT 25a. REPORT TYPE		24d. REPORT SOURCE BY MANUFACTURER 24d. REPORT SOURCE STUDY LITERATURE																			
00 1111 0005	20-MAY-2025 HEALTH PROFESSIONAL OTHER:					_															
	DATE OF THIS REPORT 03-JUL-2025	25a. REPOR	TTYPE		יםו וואוס ו																

ADDITIONAL INFORMATION

7+13. DESCRIBE REACTION(S) continued

physician and their daily work to maintain an optimal diabetic control of patients through added value services such as treatment starter kit, nutrition support through NovoDia call center, individual workshops, group workshops and free A1c test.

Patient's height: 173 cm.

Patient's weight: 81 kg.

Patient's BMI: 27.06405160.

This non-serious Solicited Report from COSTA RICA was reported by a Consumer as "Diarrhea(Diarrhea)" beginning on MAY-2025, "Headaches(Headache)" beginning on MAY-2025, "Ozempic use for Overweight and insulin resistance(Product use in unapproved indication)" beginning on APR-2025 and concerned a 46 Years old Female patient who was treated with Ozempic 0.25/0.50 mg (SEMAGLUTIDE 1.34 mg/mL) from APR-2025 and ongoing for "Overweight", "Insulin resistance",

Dosage Regimens:

Ozempic 0.25/0.50 mg: ??-APR-2025 to Not Reported, Not Reported to Not Reported (Dosage Regimen Ongoing);

Current Condition: Overweight, Insulin resistance, Low vitamin D levels.

Concomitant medications included - VITAMIN D3.

Batch Numbers:

Ozempic 0.25/0.50 mg: UNK, UNK;

Action taken to Ozempic 0.25/0.50 mg was reported as No Change.

The outcome for the event "Diarrhea(Diarrhea)" was Recovering/resolving.

The outcome for the event "Headaches(Headache)" was Recovering/resolving.

The outcome for the event "Ozempic use for Overweight and insulin resistance(Product use in unapproved indication)" was Not recovered.

Reporter's causality (Ozempic 0.25/0.50 mg) -

Diarrhea(Diarrhea): Possible Headaches(Headache): Possible

Ozempic use for Overweight and insulin resistance(Product use in unapproved indication): Unknown

Company's causality (Ozempic 0.25/0.50 mg) -

Diarrhea(Diarrhea): Possible Headaches(Headache): Possible

Ozempic use for Overweight and insulin resistance(Product use in unapproved indication): Possible

Reporter Comment: Multivitamin (non specified, non codable) used as concomitant medication for Personal taste. Materna G - Balance (Myo-inositol and probiotics) (non codable) used as concomitant medication for Insulin resistance. Treatment received is Enterogermina (non specified, non codable)

14-19. SUSPECT DRUG(S) continued

14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION
#1) Semaglutide B 1.34 mg/ml PDS290	UNK; Subcutaneous	Overweight (Overweight)	APR-2025 / Unknown;
0.25/0.5 mg (SEMAGLUTIDE 1.34 mg/mL)		Insulin resistance (Insulin	Unknown
Solution for injection; Regimen #1		resistance)	
#1) Semaglutide B 1.34 mg/ml PDS290	0.5 mg, qw; Subcutaneous	Overweight (Overweight)	Ongoing;
0.25/0.5 mg (SEMAGLUTIDE 1.34 mg/mL)		Insulin resistance (Insulin	Unknown
Solution for injection; Regimen #2		resistance)	

23. OTHER RELEVANT HISTORY continued

From/To Dates	Type of History / Notes	Description
Unknown to Ongoing	Current Condition	Vitamin D low (Vitamin D decreased);

Mfr. Control Number: 1439736

ADDITIONAL INFORMATION

23. OTHER RELEVANT HISTORY continued

From/To Dates Type of History / Notes Description